This study is looking for adults aged 18-50 who experience anxiety or depression and have difficulty with social connections. Researchers want to see if a medication called pramipexole can help improve social connectedness. Pramipexole is already approved for other conditions like Parkinson's disease. You might be eligible if you have elevated anxiety or depression, moderate social disability, and lower-than-average reward sensitivity. The study will compare pramipexole to a placebo (an inactive pill) over 6 weeks. Success will be measured by looking at brain activity during social reward anticipation, as well as behavior and self-reported feelings. The study plans to enroll about 108 people across two locations.

Study design

This is a 6-week randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either pramipexole or a placebo, and neither you nor the researchers will know which you are receiving. Approximately 108 participants will be enrolled.

What's involved

You would take either pramipexole or a placebo pill daily for 6 weeks. Your brain function, behavior, and self-reported feelings will be assessed at the beginning of the study and again at week 6.

Compensation

Not stated in the trial record.

Follow-up

Your neural activation during social reward anticipation will be measured at week 6, which is the end of the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.